Loading...

LeMaitre Vascular

Nasdaq:LMAT
Snowflake Description

Excellent balance sheet and slightly overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
LMAT
Nasdaq
$524M
Market Cap
  1. Home
  2. US
  3. Healthcare
Company description

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The last earnings update was 19 days ago. More info.


Add to Portfolio Compare Print
LMAT Share Price and Events
7 Day Returns
-3.2%
NasdaqGM:LMAT
-0.8%
US Medical Equipment
-2.1%
US Market
1 Year Returns
-18.1%
NasdaqGM:LMAT
9.6%
US Medical Equipment
1.3%
US Market
LMAT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
LeMaitre Vascular (LMAT) -3.2% -8% -10.3% -18.1% 81.2% 253.5%
US Medical Equipment -0.8% 1.1% -1.9% 9.6% 54.9% 88.9%
US Market -2.1% -4.2% 0% 1.3% 33.5% 38%
1 Year Return vs Industry and Market
  • LMAT underperformed the Medical Equipment industry which returned 9.6% over the past year.
  • LMAT underperformed the Market in United States of America which returned 1.3% over the past year.
Price Volatility
LMAT
Industry
5yr Volatility vs Market

Value

 Is LeMaitre Vascular undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of LeMaitre Vascular to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for LeMaitre Vascular.

NasdaqGM:LMAT Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 7 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.3%
Perpetual Growth Rate 10-Year US Government Bond Rate 2.7%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for NasdaqGM:LMAT
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year US Govt Bond Rate 2.7%
Equity Risk Premium S&P Global 6%
Medical Equipment Unlevered Beta Simply Wall St/ S&P Global 0.89
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.892 (1 + (1- 21%) (1.28%))
0.934
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.93
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 2.73% + (0.934 * 5.96%)
8.29%

Discounted Cash Flow Calculation for NasdaqGM:LMAT using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for LeMaitre Vascular is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

NasdaqGM:LMAT DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 8.29%)
2019 17.38 Analyst x1 16.05
2020 22.85 Analyst x1 19.48
2021 24.43 Est @ 6.93% 19.24
2022 25.82 Est @ 5.67% 18.77
2023 27.05 Est @ 4.79% 18.16
2024 28.18 Est @ 4.17% 17.47
2025 29.24 Est @ 3.74% 16.74
2026 30.24 Est @ 3.44% 15.99
2027 31.21 Est @ 3.22% 15.24
2028 32.18 Est @ 3.08% 14.50
Present value of next 10 years cash flows $171.63
NasdaqGM:LMAT DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $32.18 × (1 + 2.73%) ÷ (8.29% – 2.73%)
$594.01
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $594.01 ÷ (1 + 8.29%)10
$267.75
NasdaqGM:LMAT Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $171.63 + $267.75
$439.38
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $439.38 / 19.67
$22.34
NasdaqGM:LMAT Discount to Share Price
Calculation Result
Value per share (USD) From above. $22.34
Current discount Discount to share price of $26.62
= -1 x ($26.62 - $22.34) / $22.34
-19.2%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of LeMaitre Vascular is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for LeMaitre Vascular's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are LeMaitre Vascular's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqGM:LMAT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $1.16
NasdaqGM:LMAT Share Price ** NasdaqGM (2019-05-24) in USD $26.62
United States of America Medical Equipment Industry PE Ratio Median Figure of 64 Publicly-Listed Medical Equipment Companies 39.08x
United States of America Market PE Ratio Median Figure of 3,082 Publicly-Listed Companies 17.36x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of LeMaitre Vascular.

NasdaqGM:LMAT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:LMAT Share Price ÷ EPS (both in USD)

= 26.62 ÷ 1.16

22.98x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • LeMaitre Vascular is good value based on earnings compared to the US Medical Equipment industry average.
  • LeMaitre Vascular is overvalued based on earnings compared to the United States of America market.
Price based on expected Growth
Does LeMaitre Vascular's expected growth come at a high price?
Raw Data
NasdaqGM:LMAT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 22.98x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts
8.1%per year
United States of America Medical Equipment Industry PEG Ratio Median Figure of 55 Publicly-Listed Medical Equipment Companies 2.1x
United States of America Market PEG Ratio Median Figure of 2,120 Publicly-Listed Companies 1.5x

*Line of best fit is calculated by linear regression .

NasdaqGM:LMAT PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 22.98x ÷ 8.1%

2.83x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • LeMaitre Vascular is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on LeMaitre Vascular's assets?
Raw Data
NasdaqGM:LMAT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $6.77
NasdaqGM:LMAT Share Price * NasdaqGM (2019-05-24) in USD $26.62
United States of America Medical Equipment Industry PB Ratio Median Figure of 182 Publicly-Listed Medical Equipment Companies 4.38x
United States of America Market PB Ratio Median Figure of 5,207 Publicly-Listed Companies 1.8x
NasdaqGM:LMAT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:LMAT Share Price ÷ Book Value per Share (both in USD)

= 26.62 ÷ 6.77

3.93x

* Primary Listing of LeMaitre Vascular.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • LeMaitre Vascular is good value based on assets compared to the US Medical Equipment industry average.
X
Value checks
We assess LeMaitre Vascular's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. LeMaitre Vascular has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is LeMaitre Vascular expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
8.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is LeMaitre Vascular expected to grow at an attractive rate?
  • LeMaitre Vascular's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • LeMaitre Vascular's earnings growth is positive but not above the United States of America market average.
  • LeMaitre Vascular's revenue growth is positive but not above the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqGM:LMAT Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqGM:LMAT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 7 Analysts 8.1%
NasdaqGM:LMAT Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 7 Analysts 6.8%
United States of America Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 21.8%
United States of America Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 8.1%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.7%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqGM:LMAT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqGM:LMAT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 132 23 2
2020-12-31 121 25 19 7
2019-12-31 114 19 17 7
NasdaqGM:LMAT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 108 16 23
2018-12-31 106 20 23
2018-09-30 103 20 21
2018-06-30 104 24 22
2018-03-31 103 24 18
2017-12-31 101 23 17
2017-09-30 98 20 15
2017-06-30 96 18 14
2017-03-31 93 18 12
2016-12-31 89 17 11
2016-09-30 86 17 11
2016-06-30 82 14 9

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • LeMaitre Vascular's earnings are expected to grow by 8.1% yearly, however this is not considered high growth (20% yearly).
  • LeMaitre Vascular's revenue is expected to grow by 6.8% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqGM:LMAT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below

All data from LeMaitre Vascular Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:LMAT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 1.09 1.15 1.02 2.00
2020-12-31 0.93 1.04 0.84 7.00
2019-12-31 0.83 0.84 0.81 7.00
NasdaqGM:LMAT Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 1.16
2018-12-31 1.18
2018-09-30 1.08
2018-06-30 1.14
2018-03-31 0.93
2017-12-31 0.91
2017-09-30 0.83
2017-06-30 0.73
2017-03-31 0.63
2016-12-31 0.57
2016-09-30 0.57
2016-06-30 0.52

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if LeMaitre Vascular will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess LeMaitre Vascular's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
LeMaitre Vascular has a total score of 1/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has LeMaitre Vascular performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare LeMaitre Vascular's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • LeMaitre Vascular has delivered over 20% year on year earnings growth in the past 5 years.
  • LeMaitre Vascular's 1-year earnings growth is less than its 5-year average (26.9% vs 38.4%)
  • LeMaitre Vascular's earnings growth has not exceeded the US Medical Equipment industry average in the past year (26.9% vs 31.9%).
Earnings and Revenue History
LeMaitre Vascular's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from LeMaitre Vascular Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqGM:LMAT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 108.05 22.60 46.01 8.61
2018-12-31 105.57 22.94 45.01 8.20
2018-09-30 103.33 21.20 44.08 7.43
2018-06-30 103.99 21.93 43.74 7.16
2018-03-31 102.72 17.81 42.74 6.80
2017-12-31 100.87 17.18 42.46 6.64
2017-09-30 98.00 15.49 42.87 6.58
2017-06-30 96.40 13.68 42.75 6.35
2017-03-31 93.03 11.64 42.35 6.35
2016-12-31 89.15 10.59 40.46 6.14
2016-09-30 86.16 10.52 39.25 6.19
2016-06-30 81.77 9.39 38.05 6.08
2016-03-31 79.10 8.56 36.93 5.77
2015-12-31 77.61 7.76 36.79 5.48
2015-09-30 75.83 7.14 35.98 4.99
2015-06-30 74.31 5.99 35.99 4.67
2015-03-31 72.58 5.49 35.77 4.48
2014-12-31 70.41 3.92 35.84 4.67
2014-09-30 69.64 2.75 36.31 4.99
2014-06-30 67.47 2.53 35.85 5.18
2014-03-31 65.28 2.15 35.61 5.31
2013-12-31 63.91 3.20 34.72 5.24
2013-09-30 60.97 3.15 33.71 5.40
2013-06-30 59.47 3.10 33.02 5.36
2013-03-31 58.03 3.03 32.55 5.23
2012-12-31 56.74 2.57 31.78 5.09
2012-09-30 55.35 2.22 31.03 4.67
2012-06-30 56.26 2.77 30.68 4.38

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • LeMaitre Vascular has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • LeMaitre Vascular used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.
  • LeMaitre Vascular's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess LeMaitre Vascular's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
LeMaitre Vascular has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is LeMaitre Vascular's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up LeMaitre Vascular's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • LeMaitre Vascular is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • LeMaitre Vascular's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of LeMaitre Vascular's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 14.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from LeMaitre Vascular Company Filings, last reported 1 month ago.

NasdaqGM:LMAT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 133.09 6.70 47.46
2018-12-31 130.24 0.00 47.99
2018-09-30 125.35 0.00 45.63
2018-06-30 120.74 0.00 52.94
2018-03-31 113.47 0.00 45.39
2017-12-31 109.77 0.00 41.66
2017-09-30 106.11 0.00 37.51
2017-06-30 98.31 0.00 30.12
2017-03-31 91.62 0.00 25.81
2016-12-31 87.50 0.00 24.29
2016-09-30 86.69 0.00 34.65
2016-06-30 82.85 0.00 29.32
2016-03-31 80.62 0.00 25.94
2015-12-31 77.88 0.00 27.45
2015-09-30 74.19 0.00 23.63
2015-06-30 70.44 0.00 19.43
2015-03-31 67.93 0.00 17.03
2014-12-31 68.21 0.00 18.69
2014-09-30 67.12 0.00 18.35
2014-06-30 67.78 0.00 23.51
2014-03-31 56.24 0.00 12.50
2013-12-31 56.56 0.00 14.71
2013-09-30 55.39 0.00 13.63
2013-06-30 54.13 0.00 14.91
2013-03-31 53.34 0.00 15.30
2012-12-31 52.89 0.00 16.45
2012-09-30 51.91 0.00 20.64
2012-06-30 51.97 0.00 20.16
  • LeMaitre Vascular's level of debt (5%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 5% today).
  • Debt is well covered by operating cash flow (231.8%, greater than 20% of total debt).
  • LeMaitre Vascular earns more interest than it pays, coverage of interest payments is not a concern.
X
Financial health checks
We assess LeMaitre Vascular's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. LeMaitre Vascular has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is LeMaitre Vascular's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.28%
Current annual income from LeMaitre Vascular dividends. Estimated to be 1.28% next year.
If you bought $2,000 of LeMaitre Vascular shares you are expected to receive $26 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • LeMaitre Vascular's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.47%).
  • LeMaitre Vascular's dividend is below the markets top 25% of dividend payers in United States of America (3.76%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqGM:LMAT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 7 Analyst Estimates (S&P Global) See Below
United States of America Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 24 Stocks 1.3%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2008 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.5%
United States of America Top 25% Dividend Yield 75th Percentile 3.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqGM:LMAT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31 0.34 1.00
2019-12-31 0.34 1.00
NasdaqGM:LMAT Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-05-06 0.340 1.240
2019-05-01 0.340 1.227
2019-03-11 0.340 1.143
2019-02-19 0.340 1.149
2018-10-04 0.280 1.098
2018-07-26 0.280 0.780
2018-05-04 0.280 0.799
2018-04-25 0.280 0.844
2018-03-09 0.280 0.740
2018-02-21 0.280 0.782
2017-10-26 0.220 0.665
2017-07-27 0.220 0.608
2017-05-04 0.220 0.736
2017-04-26 0.220 0.726
2017-03-09 0.220 0.903
2017-02-21 0.220 0.983
2016-11-04 0.180 0.762
2016-10-26 0.180 0.874
2016-08-05 0.180 0.941
2016-07-27 0.180 1.061
2016-05-06 0.180 1.237
2016-05-02 0.180 1.108
2016-03-10 0.180 1.184
2016-02-24 0.180 1.240
2015-10-27 0.160 1.090
2015-07-28 0.160 1.219
2015-05-07 0.160 1.474
2015-04-28 0.160 1.726
2015-03-18 0.160 1.909
2015-02-25 0.160 2.006
2014-11-06 0.140 1.873
2014-10-28 0.140 1.945
2014-04-29 0.140 1.883
2014-03-21 0.140 1.746
2014-02-25 0.140 1.723
2013-11-07 0.120 1.496
2013-10-29 0.120 1.518
2013-08-09 0.120 1.744
2013-07-30 0.120 1.750
2013-02-26 0.120 1.902
2012-11-02 0.100 1.621
2012-07-31 0.100 1.612
2012-05-02 0.100 1.771
2012-02-27 0.100 1.769
2011-10-27 0.080 1.413
2011-07-28 0.080 1.228
2011-04-28 0.080 1.132
2011-02-28 0.080 1.183

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Whilst dividend payments have been stable, LeMaitre Vascular has been paying a dividend for less than 10 years.
  • Dividend payments have increased, but LeMaitre Vascular only paid a dividend in the past 8 years.
Current Payout to shareholders
What portion of LeMaitre Vascular's earnings are paid to the shareholders as a dividend.
  • Dividends paid are well covered by earnings (3.9x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess LeMaitre Vascular's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can LeMaitre Vascular afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. LeMaitre Vascular has a total score of 1/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of LeMaitre Vascular's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
George LeMaitre
COMPENSATION $1,404,206
AGE 53
TENURE AS CEO 26.9 years
CEO Bio

Mr. George W. LeMaitre has been Chief Executive Officer of Lemaitre Vascular, Inc. since June 1992 and has been its Chairman since 2004. Mr. LeMaitre served as the President of Lemaitre Vascular from June 1992 to July 24, 2007. It is a venture-backed medical device company that designs, manufactures and markets minimally invasive cardiovascular bypass catheters. Mr. LeMaitre worked as an investment banker at Lehman Brothers in New York, as a leveraged buyout analyst at McCown De Leeuw and as a commercial banker at Connecticut National Bank. Mr. LeMaitre holds a U.S. patent on the Expandable LeMaitre Valvulotome. He has been a Director of Vascutech Inc. since June 1992. He has been a Director of LeMaitre Vascular, Inc. since June 1992. He served as a Director of Athersys Inc. since October 1995. Mr. LeMaitre received his MBA from Stanford University's Graduate School of Business in 1992 and his BA in History from Stanford University in 1986.

CEO Compensation
  • George's compensation has been consistent with company performance over the past year, both up more than 20%.
  • George's remuneration is about average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the LeMaitre Vascular management team in years:

13.1
Average Tenure
50
Average Age
  • The average tenure for the LeMaitre Vascular management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

George LeMaitre

TITLE
Chairman & CEO
COMPENSATION
$1M
AGE
53
TENURE
26.9 yrs

Dave Roberts

TITLE
President & Director
COMPENSATION
$704K
AGE
54
TENURE
11.8 yrs

Joseph Pellegrino

TITLE
CFO, Treasurer
COMPENSATION
$671K
AGE
53
TENURE
11.8 yrs

Trent Kamke

TITLE
Senior Vice President of Operations
COMPENSATION
$454K
AGE
47
TENURE
14.3 yrs

George LeMaitre

TITLE
Founder and Chairman of Scientific Advisory Board
COMPENSATION
$138K
AGE
84
TENURE
36.3 yrs

Laurie Churchill

TITLE
Senior VP & General Counsel
AGE
47
TENURE
5.3 yrs

Kimberly Cieslak

TITLE
Vice President of Marketing
AGE
45
TENURE
16.3 yrs

Andrew Hodgkinson

TITLE
Senior Vice President of Clinical
AGE
42
TENURE
6.3 yrs
Board of Directors Tenure

Average tenure and age of the LeMaitre Vascular board of directors in years:

13
Average Tenure
61
Average Age
  • The average tenure for the LeMaitre Vascular board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Dave Roberts

TITLE
President & Director
COMPENSATION
$704K
AGE
54
TENURE
18 yrs

Joseph Pellegrino

TITLE
CFO, Treasurer
COMPENSATION
$671K
AGE
53
TENURE
2.6 yrs

George LeMaitre

TITLE
Founder and Chairman of Scientific Advisory Board
COMPENSATION
$138K
AGE
84

Larry Jasinski

TITLE
Director
COMPENSATION
$97K
AGE
61
TENURE
16.3 yrs

George LeMaitre

TITLE
Chairman & CEO
COMPENSATION
$1M
AGE
53
TENURE
15.3 yrs

John O'Connor

TITLE
Director
COMPENSATION
$102K
AGE
70
TENURE
10.7 yrs

Michael Thomas

TITLE
Director
COMPENSATION
$92K
AGE
69
TENURE
5.5 yrs

Thomas Naslund

TITLE
Member of Scientific Advisory Board

Steven Kagan

TITLE
Member of Scientific Advisory Board

Herbert Dardik

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
26. Feb 19 Sell Trent Kamke Individual 22. Feb 19 22. Feb 19 -16,604 $29.63 $-492,011
06. Aug 18 Sell David Roberts Individual 02. Aug 18 02. Aug 18 -21,005 $35.72 $-750,303
05. Jun 18 Sell George LeMaitre Individual 01. Jun 18 05. Jun 18 -48,929 $34.70 $-1,689,326
30. May 18 Sell Trent Kamke Individual 25. May 18 29. May 18 -13,733 $32.83 $-450,639
X
Management checks
We assess LeMaitre Vascular's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. LeMaitre Vascular has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What To Know Before Buying LeMaitre Vascular, Inc. (NASDAQ:LMAT) For Its Dividend

(NASDAQ:LMAT) from a dividend investor's perspective. Owning a strong business and reinvesting the dividends is widely seen as an attractive way of growing your wealth. If you are hoping to live on your dividends, it's important to be more stringent with your investments than the average punter. Regular readers know we like to apply the same approach to each dividend stock, and we hope you'll find our analysis useful. Investors might not know much about LeMaitre Vascular's dividend prospects, even though it has been paying dividends for the last eight years and offers a 1.2% yield. A low yield is generally a turn-off, but if the prospects for earnings growth were strong, investors might be pleasantly surprised by the long-term results. Before you buy any stock for its dividend however, you should always remember Warren Buffett's two rules: 1) Don't lose money, and 2) Remember rule #1. … It's good to see LeMaitre Vascular has been growing its earnings per share at 41% a year over the past 5 years. … Conclusion To summarise, shareholders should always check that LeMaitre Vascular's dividends are affordable, that its dividend payments are relatively stable, and that it has decent prospects for growing its earnings and dividend.

Simply Wall St -

Here's What LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) P/E Ratio Is Telling Us

We'll look at LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) P/E ratio and reflect on what it tells us about the company's share price. … Based on the last twelve months, LeMaitre Vascular's P/E ratio is 22.9. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

Should You Be Adding LeMaitre Vascular (NASDAQ:LMAT) To Your Watchlist Today?

In contrast to all that, I prefer to spend time on companies like LeMaitre Vascular (NASDAQ:LMAT), which has not only revenues, but also profits. … LeMaitre Vascular's Earnings Per Share Are Growing. … Careful consideration of revenue growth and earnings before interest and taxation (EBIT) margins can help inform a view on the sustainability of the recent profit growth.

Simply Wall St -

Have Insiders Been Selling LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares This Year?

So shareholders might well want to know whether insiders have been buying or selling shares in LeMaitre Vascular, Inc. … LeMaitre Vascular Insider Transactions Over The Last Year. … LeMaitre Vascular insiders didn't buy any shares over the last year

Simply Wall St -

LeMaitre Vascular, Inc. (NASDAQ:LMAT): What Can We Expect In The Future?

LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) latest earnings announcement in December 2018a … revealed

Simply Wall St -

Does Market Volatility Impact LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) Share Price?

(NASDAQ:LMAT), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

Did Business Growth Power LeMaitre Vascular's (NASDAQ:LMAT) Share Price Gain of 276%?

One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). … During five years of share price growth, LeMaitre Vascular achieved compound earnings per share (EPS) growth of 41% per year. … The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers)

Simply Wall St -

At US$31.27, Is It Time To Put LeMaitre Vascular, Inc. (NASDAQ:LMAT) On Your Watch List?

led the NASDAQGM gainers with a relatively large price hike in the past couple of weeks. … With many analysts covering the stock, we may expect any price-sensitive announcements have already been factored into the stock’s share price? … Today I will analyse the most recent data on LeMaitre Vascular’s outlook and valuation to see if the opportunity still exists

Simply Wall St -

An Examination Of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

is a company with great financial health as well as a. … Below is a brief commentary on these key aspects … If you're interested in understanding beyond my broad commentary,

Simply Wall St -

Is LeMaitre Vascular, Inc.'s (NASDAQ:LMAT) CEO Salary Justified?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does George LeMaitre's Compensation Compare With Similar Sized Companies. … has a market capitalization of US$580m, and pays its CEO total annual compensation worth US$889k.

Simply Wall St -

Company Info

Description

LeMaitre Vascular, Inc. designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature; and thrombectomy catheters, which features a silicone balloon for removing thrombi in the venous system. It also provides carotid shunts that temporarily shunt the blood to the brain during the removal of plaque from the carotid artery in a carotid endarterectomy surgery; powered phlebectomy devices to remove varicose veins; and radiopaque tape, a medical-grade tape applied to the skin that enables interventionists to cross-refer between the inside and the outside of a patient’s body, and allows them to locate tributaries or lesions beneath the skin. In addition, the company offers remote endarterectomy devices to remove plaque from arteries in the leg; valvulotomes, which cuts valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and vascular grafts to bypass or replace diseased arteries. Further, it provides vascular patches, which are used for closure of vessels after surgical intervention, as well as endarterectomy and other vascular reconstruction; vessel closure systems to attach vessels to one another with titanium clips instead of sutures; and surgical glue. LeMaitre Vascular, Inc. markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was founded in 1983 and is headquartered in Burlington, Massachusetts.

Details
Name: LeMaitre Vascular, Inc.
LMAT
Exchange: NasdaqGM
Founded: 1983
$523,648,195
19,671,232
Website: http://www.lemaitre.com
Address: LeMaitre Vascular, Inc.
63 Second Avenue,
Burlington,
Massachusetts, 01803,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM LMAT Common Stock Nasdaq Global Market US USD 19. Oct 2006
DB LHU Common Stock Deutsche Boerse AG DE EUR 19. Oct 2006
Number of employees
Current staff
Staff numbers
470
LeMaitre Vascular employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/25 00:04
End of day share price update: 2019/05/24 00:00
Last estimates confirmation: 2019/05/21
Last earnings filing: 2019/05/06
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.